SAB BIOTHERAPEUTICS, INC.: 10-Q filed 2022-05-12
What SAB BIOTHERAPEUTICS, INC. reported in its quarterly report filed 2022-05-12 (fiscal Q1 2022): 39 published measures, 79 facts as tagged in accession 0000950170-22-009722.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-05-12
- Fiscal period
- fiscal Q1 2022
- Accession
- 0000950170-22-009722 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SAB BIOTHERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 67,472,478 | USD | |
| At 2021-12-31 | 79,369,220 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 26,214,212 | USD | |
| At 2021-12-31 | 40,819,307 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 41,258,266 | USD | |
| At 2021-12-31 | 38,549,913 | USD | |
| At 2021-03-31 | 40,766,784 | USD | |
| At 2020-12-31 | 39,007,835 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 22,408,409 | USD | |
| At 2021-12-31 | 33,206,712 | USD | |
| At 2021-03-31 | 20,128,251 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 985,863 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 1,409,834 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -10,293,508 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 9,453,495 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 1,357,324 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 1,890,156 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 11,803,077 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 16,927,734 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -5,562,167 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -45,471 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1,280,934 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -1,890,156 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -28,143,088 | USD | |
| At 2021-12-31 | -29,128,951 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 43,113,353 | shares | 90 |
| 2021-01-01 to 2021-03-31 | 25,973,406 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 45,816,651 | shares | 90 |
| 2021-01-01 to 2021-03-31 | 28,072,567 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 0.02 | USD/shares | 90 |
| 2021-01-01 to 2021-03-31 | 0.05 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 0.02 | USD/shares | 90 |
| 2021-01-01 to 2021-03-31 | 0.05 | USD/shares | 90 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 92,281 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 24,973,432 | USD | |
| At 2021-12-31 | 24,314,455 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 897,600 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 349,115 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -6,707,339 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 813,924 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 36,169,737 | USD | |
| At 2021-12-31 | 48,420,239 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 72,022 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 75,192 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 18,255,884 | USD | |
| At 2021-12-31 | 24,683,562 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 4,981,385 | USD | |
| At 2021-12-31 | 4,458,525 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 18,510,416 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 16,113,810 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 13,324,344 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 12,782,004 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 42,955,121 | shares | |
| At 2021-12-31 | 43,487,279 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 74,918,250 | USD | |
| At 2021-12-31 | 67,674,515 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 2,351,193 | USD | |
| At 2021-12-31 | 2,615,204 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 2,513,509 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 3,763,769 | USD | |
| At 2021-12-31 | 3,220,016 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 1,078,144 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 1,409,834 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 985,863 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 1,409,834 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 5,186,072 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 3,331,806 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 636,235 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 235,959 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 7,785,483 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 595,910 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 72,022 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 75,192 | USD | 90 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 311,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 268,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 3,775,713 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -8,976,089 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 522,816 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -3,836,356 | USD | 90 |
Inspect the source
- Entity
- SAB BIOTHERAPEUTICS, INC. / CIK 0001833214
- Captured
- 2026-09-21T17:30:30.932Z
- SEC response SHA-256
77a9d5e74034d5680bee440489a5722f0205b7102ec23dd33e3ff98bbc2065ac
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001833214.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))